Comparative Pharmacology
Head-to-head clinical analysis: ALLERNAZE versus BENADRYL PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERNAZE versus BENADRYL PRESERVATIVE FREE.
ALLERNAZE vs BENADRYL PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at histamine H1 receptors, preventing histamine-mediated symptoms such as itching, sneezing, and vasodilation.
Diphenhydramine competitively antagonizes histamine at H1-receptors on effector cells, leading to relief of allergic symptoms. It also possesses anticholinergic, antiemetic, sedative, and local anesthetic effects.
5 mg orally once daily at bedtime, maximum 10 mg per day.
25-50 mg IV/IM every 4-6 hours as needed; maximum single dose 100 mg, maximum daily dose 400 mg.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. Clinical context: Allows for twice-daily dosing in allergic rhinitis; steady-state reached in 2-3 days.
Terminal elimination half-life: 4-8 hours (mean ~5 hours). Prolonged in hepatic impairment (up to 2-fold) and elderly (7-12 hours).
Primarily renal (70-80% as unchanged drug and metabolites), with approximately 5-10% biliary/fecal elimination.
Primarily renal (90% as metabolites and unchanged drug); ~1% excreted in feces via bile. Unchanged diphenhydramine accounts for <5% of urinary recovery.
Category C
Category C
Antihistamine
Antihistamine